首页> 外文OA文献 >Results of a Phase II Trial of Gemcitabine Plus Doxorubicin in Patients with Recurrent Head and Neck Cancers: Serum C18-Ceramide as a Novel Biomarker for Monitoring Response

【2h】

Results of a Phase II Trial of Gemcitabine Plus Doxorubicin in Patients with Recurrent Head and Neck Cancers: Serum C18-Ceramide as a Novel Biomarker for Monitoring Response

机译：吉西他滨加入多柔比蛋白在复发性头部和颈部癌症患者中试验的结果：血清C18-神经酰胺作为一种用于监测反应的新型生物标志物

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Sahar A. Saddoughi; Elizabeth Garrett-Mayer; Uzair Chaudhary; Paul E. OBrien; Larry B. Afrin; Terry A. Day; M. Boyd Gillespie; Anand K. Sharma; Christina S. Wilhoit; Robin Bostick; Can E. Senkal; Yusuf A. Hannun; Jacek Bielawski; George R. Simon; Keisuke Shirai; Besim Ogretmen;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C-ceramide as a novel biomarker for monitoring response. [J] . Saddoughi SA, Garrett Mayer E, Chaudhary U, Clinical cancer research: an official journal of the American Association for Cancer Research . 2011,第18期

机译：吉西他滨加阿霉素在复发性头颈癌患者中进行的II期临床试验结果：血清C-神经酰胺可作为监测反应的新型生物标志物。
2. Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. [J] . Ferrandina G, Ludovisi M, Corrado G, Gynecologic Oncology: An International Journal . 2008,第2期

机译：Ca125反应标准和RECIST标准的预后作用：吉西他滨与聚乙二醇化脂质体阿霉素在复发性卵巢癌中的MITO-3 III期临床试验结果分析。
3. Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group. [J] . Schrijvers D, Johnson J, Jiminez U, Journal of Clinical Oncology . 1998,第3期

机译：复发性或转移性头颈癌患者中通过干扰素α-2b调节顺铂/氟尿嘧啶化疗的III期试验。头颈干扰素合作研究组。
4. Using a Bayesian Feature-selection Algorithm to Identify Dose-response Models Based on the Shape of the 3D Dose-distribution: An Example from a Head-and-neck Cancer Trial [C] . Buettner Florian, Gulliford Sarah L., Webb Steve, Ninth International Conference on Machine Learning and Applications . 2010

机译：使用贝叶斯特征选择算法识别基于3D剂量分布形状的剂量反应模型：以头颈癌试验为例
5. Evaluation of a randomized clinical trial of a psychoeducational intervention on long-term quality of life, negative affect, progression and survival in head and neck cancer patients. [D] . Trevino, Lara A. 2011

机译：心理教育干预对头颈部癌症患者的长期生活质量，负面影响，进展和生存的随机临床试验评估。
6. Results of a Phase II Trial of Gemcitabine plus Doxorubicin in Patients with Recurrent Head and Neck Cancers: Serum C18-ceramide as a Novel Biomarker for Monitoring Response [O] . Sahar A. Saddoughi, Elizabeth Garrett-Mayer, Uzair Chaudhary, -1

机译：吉西他滨加入多柔比蛋白在复发性头部和颈部癌症患者中试验的结果：血清C18-神经酰胺作为一种用于监测反应的新型生物标志物
7. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group Study [O] . Schornagel J.H., Verweij J., Mulder P.H.M. de, 1995

机译：乙草胺酯与甲氨蝶呤在头颈部转移性和/或复发性鳞状细胞癌患者中的III期随机试验：欧洲癌症头颈部癌研究与治疗组织合作研究

Results of a Phase II Trial of Gemcitabine Plus Doxorubicin in Patients with Recurrent Head and Neck Cancers: Serum C18-Ceramide as a Novel Biomarker for Monitoring Response

著录项

引文网络

相似文献

相关主题

期刊订阅